Audentes Therapeutics Overview

  • Founded
  • 2012
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 354
Employees
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $2.15B
Latest Deal Amount

Audentes Therapeutics General Information

Description

Operator of a biotechnology platform intended to offer gene therapy treatments for serious rare diseases. The company's platform offerstherapies for pompe diseases, myotonic dystrophy and other life threatening diseases, enabling doctors to treat patients suffering from diseases caused by single-gene defects.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Parent Company
Primary Office
  • 600 California Street
  • 17th Floor
  • San Francisco, CA 94108
  • United States
+1 (415) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Audentes Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Merger/Acquisition 15-Jan-2020 $2.15B 00000 00.00 Completed Generating Revenue
9. PIPE 01-Jan-2019 00000 Completed Generating Revenue
8. Secondary Transaction - Open Market 00000 Completed Generating Revenue
7. Secondary Transaction - Private 17-May-2018 00000 Completed Generating Revenue
6. IPO 20-Jul-2016 0000 00000 00000 Completed Generating Revenue
5. Later Stage VC (Series C) 08-Oct-2015 0000 00000 00000 Completed Product Development
4. Accelerator/Incubator 03-Mar-2015 000.00 Completed Product Development
3. Early Stage VC (Series B) 02-Dec-2014 000.00 000.00 00000 Completed Product Development
2. Early Stage VC (Series A) 18-Jul-2013 $30M $31.4M 000.00 Completed Startup
1. Seed Round 21-Dec-2012 $1.4M $1.4M 0000 Completed Startup
To view Audentes Therapeutics’s complete valuation and funding history, request access »

Audentes Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series B 0,000,000 00.000000 00 00.00 00.00 00 00.00 00.00
Series A 11,199,876 $0.000010 8% $2.68 $2.68 1x $2.68 29.67%
Series Seed 1,400,000 $0.000010 8% $1 $1 1x $1 3.71%
To view Audentes Therapeutics’s complete cap table history, request access »

Audentes Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Operator of a biotechnology platform intended to offer gene therapy treatments for serious rare diseases. The company's
Biotechnology
San Francisco, CA
354 As of 2021
00000
0.00 0000-00-00
000000&0 00000

00000000

consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut
0000000000000
Bedford, MA
000 As of 0000
00000
0000 0000-00-00
000000000 00000

00000000

empor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitatio
0000000000000
Gaithersburg, MD
00 As of 0000
00000
0000 0000-00-00
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Audentes Therapeutics Competitors (63)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Homology Medicines Formerly VC-backed Bedford, MA 000 00000 000000000 00000
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
000 000000000000 Venture Capital-Backed Ann Arbor, MI 0 000.00 00000000000 000.00
0000000000 0000000 Formerly VC-backed Novato, CA 000 00000 000000000 00000
00000000 Private Equity-Backed Carrollton, TX 00 000.00 00 000000 000.00
You’re viewing 5 of 63 competitors. Get the full list »

Audentes Therapeutics Executive Team (22)

Name Title Board Seat Contact Info
Megan Baierlein Chief Operating Officer & Senior Vice President
Kevin Baker Ph.D Senior Vice President, Preclinical Development
Ted Slocomb Vice President, Global Market Access
Barry Byrne Ph.D Advisor
You’re viewing 4 of 22 executive team members. Get the full list »

Audentes Therapeutics Board Members (18)

Name Representing Role Since
Kush Parmar Ph.D 5AM Ventures Board Member 000 0000
Percival Barretto-Ko Audentes Therapeutics Board Member 000 0000
Toru Yoshimitsu Audentes Therapeutics Board Member 000 0000
You’re viewing 3 of 18 board members. Get the full list »

Audentes Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Audentes Therapeutics Former Investors (18)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
5AM Ventures Venture Capital Minority 000 0000 000000 0
Aisling Capital Venture Capital Minority 000 0000 000000 0
Asset Management Ventures Venture Capital Minority 000 0000 000000 0
Cormorant Asset Management Hedge Fund Minority 000 0000 000000 0
Cowen Healthcare Investments Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 18 investors. Get the full list »

Audentes Therapeutics Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000000 00000000 01-Sep-2015 000000000000000000 Biotechnology 0000000 000000000
To view Audentes Therapeutics’s complete acquisitions history, request access »